Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Peritoneal Dialysis III: Nursing Management

Peritoneal Dialysis III: Nursing Management

Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...

Esophageal Varices-II: Clinical Features and Management

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...

Myocarditis IV: Nursing Management

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...

Dysrhythmias VII: Nursing Management of Dysrhythmias

Dysrhythmias VII: Nursing Management of Dysrhythmias

Nursing management of dysrhythmias involves the following:AssessmentSubjective Assessment:The initial step involves gathering patient-reported symptoms such as dizziness, palpitations, and chest discomfort. It is crucial to collect a detailed history, including previous heart conditions, current medication use, and lifestyle factors like caffeine and alcohol consumption.Objective Assessment:This involves observing clinical signs such as jugular venous distention, cool and pale skin, and...

Angina V: Nursing Management

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...

Disorders of Erythrocytes

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Monographic consultation of onconephrology. Rationale and implementation.

Nefrologia·2022

Same author

Oral hydration as a safe prophylactic measure to prevent post-contrast acute kidney injury in oncologic patients with chronic kidney disease (IIIb) referred for contrast-enhanced computed tomography: subanalysis of the oncological group of the NICIR study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2021

Same author

Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study.

Clinical kidney journal·2021

Same author

Monographic consultation of onconephrology. Rationale and implementation.

Nefrologia·2020

Same author

Post-contrast acute kidney injury in cancer patients.

Nefrologia·2019

Same author

Onco-Nephrology: Cancer, chemotherapy and kidney.

Nefrologia·2019

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

Published on: January 19, 2024

Insights in anemia management.

Angel L M de Francisco¹, Celestino Piñera

¹Servicio de Nefrología, Hospital Universitario Valdecilla, Santander, Spain.

Contributions to Nephrology

|May 3, 2008

Summary

Anemia in chronic kidney disease (CKD) treatment faces ongoing questions regarding optimal hemoglobin (Hb) targets. Current evidence suggests avoiding Hb levels above 12 g/dl due to increased risks.

Area of Science:

Nephrology
Hematology
Clinical Pharmacology

Background:

Anemia in chronic kidney disease (CKD) management remains complex, with ongoing debate surrounding optimal hemoglobin (Hb) targets.
Current literature advises against Hb targets exceeding 12 g/dl, and highlights increased risks with targets above 13 g/dl.

Purpose of the Study:

To review the current controversies and challenges in managing anemia in CKD patients.
To discuss the implications of hemoglobin variability during erythropoiesis-stimulating agent (ESA) therapy.
To examine the association between ESAs, pure red cell aplasia (PRCA), and biopharmaceutical immunogenicity.

Main Methods:

Literature review of studies on anemia in CKD, Hb targets, and ESA therapy.
Analysis of data regarding hemoglobin cycling and its association with mortality.

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Related Experiment Videos

Last Updated: Jul 5, 2026

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

Published on: January 19, 2024

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Discussion of the Pure Red Cell Aplasia (PRCA) registry (PRIMS) and its implications for ESA safety and biopharmaceutical immunogenicity.

Main Results:

Optimal Hb targets for CKD patients are debated, with evidence against upper limits >12 g/dl and clear risks >13 g/dl.
Hemoglobin fluctuations are common with ESAs, and while studies suggest a link to mortality, further clinical trials are needed.
A significant majority of pure red cell aplasia (PRCA) cases were linked to ESA therapy, particularly after a formulation change.

Conclusions:

CKD anemia treatment requires careful consideration of Hb targets and variability, with ongoing research needed.
The PRIMS registry provides a model for assessing ESA immunogenicity, highlighting broader concerns for biopharmaceuticals.
Understanding ESA-associated PRCA is crucial for both the medical community and the biotechnology industry.